0
0
Home » Pharmaceuticals

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Global Clinical Trials Review, 2022

GlobalData’s clinical trial report, “Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Global Clinical Trials Review, 2022″ provides an overview of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

What are the market dynamics of the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

The number of waldenstrom macroglobulinemia clinical trials conducted globally, has decreased by 22% for the period 2016-2020. The average number of patients enrolled was highest in the year 2018. As of November 2021, over 50% of trials have been sponsored by institutions followed by companies. Out of 314 completed trials, 236 trials have results and over 80% of trials reached end points. There were 196 clinical trials in progress and 314 trials were completed. The trials that were terminated/suspended or withdrawn accounted to 93. This was due to the lack of efficacy, safety, and lack of accrual of subjects. There were 196 clinical trials in progress of which 37% (73 trials) were in Phase I study. There were 237 clinical trials in Phase II, of which 57 clinical trials were in progress for the time period of 1995-2021.

What are the top regions and countries in the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

In total there were 620 clinical trials conducted on waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), as of November 2021, of these 434 clinical trials were in North America. More than 55% of the clinical trials were conducted in North America.

Asia-Pacific: As of November 2021, in the Asia-Pacific region, China has the highest number of waldenstrom macroglobulinemia clinical trials followed by Australia, South Korea, Japan, and New Zealand.

Europe: Among the European countries, Italy has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021, followed by France, the UK, Germany, and Spain.

North America: In the country-wise analysis, the US has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021 followed by Canada and Mexico.

Middle East and Africa: Israel has the highest number of waldenstrom macroglobulinemia clinical trials, as of November 2021 followed by South Africa, Saudi Arabia, and Egypt.

Central and South America: Brazil has the highest number of waldenstrom macroglobulinemia clinical trials, in the region followed by Argentina, Colombia, Chile, and Peru.

G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, The US has the highest proportion of waldenstrom macroglobulinemia in oncology clinical trials as of November 2021. In total there were 679 clinical trials conducted on waldenstrom macroglobulinemia, as of November 2021 in G7 Countries, of these 423 clinical trials were in the US. There were 131 clinical trials in progress and 273 trials are completed. The trials that are terminated/suspended or withdrawn accounted to 90. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of waldenstrom macroglobulinemia to oncology clinical trials as of November 2021. In total there were 125 clinical trials conducted on waldenstrom macroglobulinemia, as of November 2021 in E7 Countries, of these 78 clinical trials were in China. There were 60 clinical trials in progress and 22 trials were completed. The trials that were terminated/suspended or withdrawn accounted to four. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by regions

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global waldenstrom macroglobulinemia therapeutics clinical trials sector?

As of November 2021, Gilead Sciences Inc has conducted the highest number of waldenstrom macroglobulinemia clinical trials followed by Takeda Pharmaceutical Co Ltd. Other major players include AbbVie Inc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co, AstraZeneca Plc, BeiGene Ltd, Amgen Inc, and Novartis AG.

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by key companies

Global waldenstrom macroglobulinemia therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key countries The US, China, Italy, Canada, France, the UK, Australia, Germany, Spain, and South Korea
Key companies Gilead Sciences Inc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co, AstraZeneca Plc, BeiGene Ltd, Amgen Inc, and Novartis AG

 Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for un-accomplishment.
  • The Report provides enrollment trends for the past five years.
  • Report provides the latest news for the past three months.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

Gilead Sciences Inc

Takeda Pharmaceutical Co Ltd

AbbVie Inc

Johnson & Johnson

Bristol-Myers Squibb Co

F. Hoffmann-La Roche Ltd

AstraZeneca Plc

BeiGene Ltd

Amgen Inc

Novartis AG

Table of Contents

Table of Contents

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Clinical Trials by G7 Countries: Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Disclaimer

Source

List of Tables

List of Tables

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Region, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, North America, Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*

Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, G7 Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, E7 Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

List of Figures

List of Figures

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Region (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*

Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, G7 Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) to Oncology Clinical Trials, E7 Countries (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Phase (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

GlobalData Methodology

Frequently Asked Questions

The key countries in the global waldenstrom macroglobulinemia therapeutics clinical trials sector are the US, China, Italy, Canada, France, the UK, Australia, Germany, Spain, and South Korea.

The key companies in the global waldenstrom macroglobulinemia therapeutics clinical trials sector are Gilead Sciences Inc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co, AstraZeneca Plc, BeiGene Ltd, Amgen Inc, and Novartis AG.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports